Perrigo receives FDA approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)

Download PDF Copy

Reviewed

Mar 24 2009

Perrigo Company has announced that it has received final approval from the U.S. Food and Drug Administration to market Sulfacetamide Sodium Topical Suspension, 10% (Lotion).

The product has been determined to be therapeutically equivalent (AB) to Sanofi-Aventis' Klaron(R) (Sodium Sulfacetamide) Lotion, 10%, which is indicated for the topical treatment of acne. Klaron(R) Lotion had sales of approximately $15 million for the 12 months ended January 2009, as measured by Wolters Kluwer Health.

Perrigo's Chairman and CEO Joseph C. Papa concluded, "This approval is another example of our commitment to invest in and bring new products to market. It further demonstrates our strategy to deliver quality affordable healthcare both behind and over the counter."

Source:

http://www.perrigo.com/

Posted in: Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Social media food shows like Mukbang are changing how people eat

Fast food’s grip on American diets weakens as younger adults cut back

Food insecurity raises long COVID risk while SNAP support cuts it

Can changing food texture reduce how much we eat? Dutch study investigates

Can a short message change how we think about expired food?

Asthma and multiple allergies raise the risk of failed oral food challenges

Mediterranean diet during pregnancy cuts babies’ food allergy risk

Common food additives may trigger childhood asthma

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.